KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $140000.0.

  • Travere Therapeutics' Capital Expenditures changed N/A to $140000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $222000.0, marking a year-over-year increase of 10747.66%. This contributed to the annual value of $668000.0 for FY2023, which is 24973.82% up from last year.
  • As of Q3 2025, Travere Therapeutics' Capital Expenditures stood at $140000.0.
  • In the past 5 years, Travere Therapeutics' Capital Expenditures ranged from a high of $4.5 million in Q1 2021 and a low of $3000.0 during Q2 2023
  • Moreover, its 5-year median value for Capital Expenditures was $92500.0 (2021), whereas its average is $441571.4.
  • Its Capital Expenditures has fluctuated over the past 5 years, first tumbled by 9708.57% in 2022, then skyrocketed by 263333.33% in 2024.
  • Travere Therapeutics' Capital Expenditures (Quarter) stood at $154000.0 in 2021, then plummeted by 80.52% to $30000.0 in 2022, then fell by 16.67% to $25000.0 in 2023, then soared by 228.0% to $82000.0 in 2024, then skyrocketed by 70.73% to $140000.0 in 2025.
  • Its Capital Expenditures stands at $140000.0 for Q3 2025, versus $82000.0 for Q2 2024 and $25000.0 for Q4 2023.